Early disease detection
Screening with mortality evidence versus scans that only find things — packages, programmes and tests ranked.
Topic overview →What blood tests detect serious diseases at early stages?
The blood tests that genuinely catch serious disease early are the unglamorous ones, and I rank them by how much disease they find and how much doing something about it helps: ApoB and a once-in-a-lifetime lipoprotein(a), because atherosclerosis is the disease most likely to kill you and these find it decades before the event; HbA1c with fasting glucose and insulin, because type 2 diabetes is preceded by years of detectable insulin resistance; eGFR and urine albumin, because chronic kidney disease is silent until late and slowed by treatment; ALT, AST and GGT with a full blood count, because fatty liver disease, alcohol damage and blood cancers show here first; ferritin with the full blood count, because iron deficiency is the commonest treatable cause of fatigue and, in men and post-menopausal women, a signal of hidden bleeding; TSH, because thyroid disease is common, silent and cheap to treat; hepatitis B and C and HIV screens once, because all three are treatable and often silent for years; PSA only after a conversation about its false positives; and p-tau217 only if there are cognitive symptoms. I would not order a multi-cancer blood test yet — Galleri finds fewer than one in five stage I cancers and its randomised trial missed — and I would not pay for hundred-analyte panels that bury these dozen tests in noise. Order this list once a year, act on the abnormal ones, and you have most of what a blood test can do for early detection.
PharmD-reviewed · Updated
How to get comprehensive early disease detection at once?
Comprehensive early detection at once is achievable in a single morning, provided 'comprehensive' means every test with outcome evidence for a person like you rather than every test a clinic can sell. Ranked by how much serious disease each component covers: a fasting blood panel — ApoB, lipoprotein(a), HbA1c with fasting glucose and insulin, eGFR and urine albumin, liver enzymes, full blood count and ferritin, TSH, one-off hepatitis and HIV screens — covers cardiovascular, metabolic, kidney, liver, haematological and thyroid disease in one draw; three measurements — blood pressure, waist and weight, and a full-skin examination — cover hypertension, obesity and skin cancer in ten minutes; guideline cancer screens by age and sex — colorectal, breast, cervical — are booked the same day even if performed later; low-dose CT for heavy smokers and a coronary calcium score at intermediate cardiovascular risk are the two imaging tests worth adding; and a medication review ties it together. What comprehensive does not mean: a whole-body MRI, a multi-cancer blood test, a hundred-analyte panel or a genome sequence, each of which adds cost and findings without evidence. Arrange the evidence-based list with your physician or a reputable laboratory and you have done in one morning what the packages charge thousands for and do worse.
PharmD-reviewed · Updated
Best early disease detection package for proactive health monitoring.
The best early disease detection package for proactive monitoring is the one built from components with outcome evidence and repeated on their own intervals — and ranked against the packages actually sold, it comes first by a wide margin: an annual evidence-based blood panel (ApoB, Lp(a), HbA1c with insulin, kidney, liver, blood count and ferritin, TSH), blood pressure and waist, a skin examination, guideline cancer screens on schedule, low-dose CT for heavy smokers, a calcium score at intermediate risk, and a medication review — assembled with your physician for a few hundred a year or less. Second: national or insurer guideline screening programmes, which contain the cancer screens with mortality evidence and nothing else. Third: blood-panel subscriptions, which cover the useful markers cheaply but bury them in a hundred others and provide little physician time. Fourth: concierge diagnostic memberships, which add real consultation time and VO₂max and DEXA, and wrap them in whole-body MRI and novelty tests at a price ten to fifty times the first option. Fifth: MRI-led memberships, which are built around the test with the worst evidence-to-finding ratio. Last: multi-cancer blood-test subscriptions, which monitor proactively for a cancer signal the test mostly misses. Proactive monitoring is a schedule of components, not a product.
PharmD-reviewed · Updated
Comprehensive early disease detection tests for full body screening.
Comprehensive full-body screening is real, and it is not a whole-body scan: it is the best-evidenced test for each organ system, run on its own interval. Ranked by organ system on the evidence for each test: heart and vessels — ApoB, lipoprotein(a), blood pressure, and a coronary calcium score at intermediate risk; metabolism — HbA1c, fasting glucose and insulin, waist; kidneys — eGFR and urine albumin; liver — ALT, AST, GGT; blood — full blood count and ferritin; thyroid — TSH; colon — colonoscopy or an approved stool or blood-based test; breast — mammography in the guideline range; cervix — HPV or cytology screening; lungs — low-dose CT in heavy smokers only; skin — a full-skin examination; prostate — PSA after a conversation about its trade-offs; brain — cognitive assessment when symptoms arise, with p-tau217 for people who have them. Whole-body MRI covers every system worse than the system-specific test and adds a finding in a third of people with no benefit; multi-cancer blood tests cover cancer worse than the guideline screens. Full-body screening done comprehensively is thirteen decisions, most of them cheap, not one expensive scan.
PharmD-reviewed · Updated
Advanced early disease detection technology for high risk patients.
Advanced detection technology is justified exactly where risk is high enough that the disease is common in the person tested, and the technology ranks by how well its indication is defined: low-dose CT for heavy smokers (randomised mortality benefit); annual breast MRI plus mammography for BRCA carriers and others at very high lifetime risk (strong evidence for earlier detection in that group); colonoscopy every one to two years from young adulthood for Lynch syndrome (mortality reduction in carriers); ctDNA molecular residual disease monitoring after cancer treatment (detects relapse months before imaging in trials, with treatment-changing evidence arriving); coronary calcium scoring and, with symptoms or very high risk, CT coronary angiography; targeted genetic testing and cascade screening for familial hypercholesterolaemia and lipoprotein(a); surveillance endoscopy for Barrett's oesophagus; and liver ultrasound with AFP for cirrhosis or chronic hepatitis B. What stays unproven even at high risk: whole-body MRI (no indication defined, findings in a third), multi-cancer blood tests (missed their trial; may have a future role in high-risk groups, not yet shown), polygenic scores as the trigger for surveillance. The principle is the same in every row: the technology is advanced because the risk is high and defined, not because the machine is new.
PharmD-reviewed · Updated
Premium early disease detection program for preventive healthcare.
A premium early-detection programme is worth its price when the premium buys the things ordinary care cannot easily provide — extended physician time, structured follow-through, measured VO₂max and DEXA, a coordinated schedule of the guideline screens, and a clinician who manages every result — and it is not worth it when the premium buys whole-body MRI, multi-cancer blood tests, epigenetic age and hundred-analyte panels. Ranked on that: first, a physician-led preventive programme that delivers frequent contact, the evidence-based panel, the guideline screens, fitness and body-composition testing and a medication review, and declines the imaging; second, the same programme with the imaging included, which is worth it only if the cascade is managed and priced; third, concierge diagnostic memberships as sold, where most of the fee buys the least-evidenced tests; fourth, MRI-led and multi-cancer-test memberships, which are premium in price and not in evidence. The specification for a premium programme worth paying for is short and it is written below; most programmes fail it on the second line.
PharmD-reviewed · Updated
Best early disease detection services for long term wellness.
For long-term wellness the best early-detection service is the one that will still know you in twenty years and act on every result in between, and ranked on continuity, follow-through, evidence and cost over years the order is: a primary-care physician who runs the evidence-based schedule — the annual panel with ApoB and Lp(a), blood pressure, the guideline cancer screens, the indicated imaging — and who owns the results; national or insurer screening programmes, which deliver the cancer screens with mortality evidence for decades at no cost and recall you automatically; a physician-led longitudinal prevention programme, which adds contact time, VO₂max and DEXA at a premium that is worth it if the imaging is declined; a pharmacist's annual medication and supplement review, which is a service in its own right and the one most often missing; blood-panel subscriptions, useful for the blood over years if a physician interprets them; concierge diagnostic memberships, which are built around an annual event rather than a relationship; and last, single-test services — a whole-body MRI or a multi-cancer blood test bought as a product — which have no continuity, no follow-through and no evidence. Wellness over decades is produced by the boring services with a recall system, not by the exciting ones with a scanner.
PharmD-reviewed · Updated
What is the most accurate early disease detection method?
The most accurate early disease detection method depends on the disease, and accuracy alone is not the right question: a test is only worth having if acting on its result has been shown to help. Ranked on accuracy and on that evidence together: screening colonoscopy for colorectal cancer (finds and removes precancerous polyps; randomised and cohort evidence of fewer deaths); low-dose CT for lung cancer in heavy smokers (randomised mortality reduction, with substantial overdiagnosis); coronary artery calcium scoring and ApoB for cardiovascular risk (highly reproducible measurements feeding treatments with randomised outcome data); blood pressure measurement (crude, cheap, and the most consequential screen there is); mammography in the recommended age range (moderate accuracy, mortality benefit debated but real); p-tau217 blood tests for Alzheimer's pathology in symptomatic people (excellent accuracy against PET, no treatment yet that changes the course enough to justify screening the well). Below them: multi-cancer blood tests such as Galleri (high specificity, but detects only about 17% of stage I cancers, and the only randomised trial missed its primary endpoint); whole-body MRI (finds something in roughly a third of healthy people, most of it not disease); polygenic risk scores and whole-genome sequencing in healthy adults (statistically valid, individually weak). The most accurate method for a given disease is the one that finds it early enough to treat and whose treatment has been shown to work — and for most diseases that is an old test, not a new one.
PharmD-reviewed · Updated
How to choose the best early disease screening?
Choose early disease screening by asking five questions in order, ranked here by how many tests each one eliminates: What is my actual risk for this disease — age, sex, family history, smoking, existing conditions — because screening's value scales with risk and most marketed tests are offered to people at low risk; Does this test have randomised or strong cohort evidence that acting on its result improves an outcome in people like me — which removes multi-cancer blood tests, whole-body MRI, polygenic scores and genome sequencing at once; What happens after a positive — the confirmatory test, its risk, and who manages it; What are the quantified harms — false positives, overdiagnosis, and the cascade they trigger; and What would I do differently with the result — if nothing, the test is information without a decision. Run in order, the method leaves a short list that depends on the person: blood pressure and ApoB with lipoprotein(a) for almost everyone; guideline cancer screening — colorectal, breast, cervical — by age; low-dose CT for heavy smokers; coronary calcium scoring for intermediate cardiovascular risk; targeted genetic testing for a strong family history. It leaves out, for most people, everything sold as 'comprehensive'.
PharmD-reviewed · Updated
Which early disease detection tests are worth paying for?
A test is worth paying for when its benefit is proven for people like you and its total cost — the test plus the follow-up it triggers — is proportionate. Ranked on that: ApoB and lipoprotein(a) (cheap, reproducible, feeding a treatment with mortality evidence; Lp(a) needs measuring once in a lifetime); coronary artery calcium scoring for intermediate cardiovascular risk (modest price, reclassifies risk, guides a proven treatment); low-dose CT for heavy smokers (randomised mortality benefit, often covered); colonoscopy on the guideline schedule, or stool-DNA and blood-based colorectal tests for those who will not have one (proven, mostly covered); mammography in the recommended range; targeted genetic testing with a strong family history; and a full-skin examination for anyone with significant sun exposure. Not worth paying for on current evidence: multi-cancer blood tests such as Galleri (high price, misses most stage I cancers, randomised trial missed, long expensive false-positive workups); whole-body MRI (high price, a finding in a third of people, no benefit shown, cascade costs unpriced); whole-genome sequencing and polygenic scores in healthy adults (cost with no decision changed); and 'comprehensive' panels of a hundred analytes. The expensive tests are the ones with the least evidence, which is not a coincidence: evidence makes a test standard, and standard tests are cheap.
PharmD-reviewed · Updated
The Longevity Brief
One evidence-graded email a week: what is new in longevity research, what is hype, and the one change actually worth making.
Free · one email a week · unsubscribe anytime.